Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
reHA
- Development stage
- Unknown
- Lead developer
- Salf
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Intraperitoneal
01
Overview
reHA is a medical device formulation of high-molecular-weight sodium hyaluronate (hyaluronic acid) developed by Salf S.p.A. and investigated by the Azienda Ospedaliero-Universitaria di Bologna for the treatment of decompensated liver cirrhosis and ascites. While reHA is CE-marked for the prevention of post-surgical adhesions, it is being repurposed for intraperitoneal administration in patients with cirrhosis to stabilize the peritoneal membrane and modulate the local inflammatory environment. The mechanism of action involves the physical properties of hyaluronic acid as a lubricant and barrier, as well as its biological activity as a ligand for receptors such as CD44 and the hyaluronan-mediated motility receptor (RHAMM). By binding to these receptors, reHA may reduce the production of pro-inflammatory cytokines and improve the integrity of the peritoneal mesothelium, thereby potentially decreasing the accumulation of ascitic fluid and improving clinical outcomes in patients with advanced liver disease.
- Brand names
- reHA
- Other names
- re-equilibrated Hyaluronic Acidsodium hyaluronatehyaluronic acid
02
Targets
CD44 (CD44 antigen)RHAMM (Hyaluronan-mediated motility receptor)HMMR
Beyond the preview
Go deeper on reHA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on reHA.